Clinical Trial Update: Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial investigating AAV1/SERCA2a gene transfer in chronic heart failure was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• AAV1/SERCA2a gene transfer (AAV1/SERCA2a)

Snippet

Sponsor: Imperial College London | Conditions: Chronic Heart Failure, Patients That Have Received a Left Ventricular Assist Device | Phase 2 | Status: TERMINATED | Results posted: 2020-02-25